Stock SYNTA PHARMACEUTICALS CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Synta Pharmaceuticals Corp. Nasdaq

Equities

US87162T2069

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Synta Pharmaceuticals Corp.
06-11 Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM
06-06 Madrigal Pharmaceuticals Reports Positive Results in New Analysis of Phase 3 Trial of NASH Drug Rezdiffra MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM
Madrigal Pharmaceuticals Reports Positive Results in New Analysis of Phase 3 Trial of NASH Drug Rezdiffra
MT
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
AQ
Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra Presented at the EASL Congress
CI
Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
AQ
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
AQ
Certain Common Stock of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Pre Funded Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Performance Stock Units of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Restricted Stock Units of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Options of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing
MT
B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating
MT
UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
MT
Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell
MT
Transcript : Madrigal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
Madrigal: Q1 Earnings Snapshot
AQ
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDGL Stock
  4. Stock
  5. News Synta Pharmaceuticals Corp.